Maternal Screen-1st Trimester Dual Marker Test (Serum) _FMF

This test measures the levels of PAPPa (pregnancy-associated plasma protein A) and Free HCG (human chorionic gonadotropin) in a pregnant woman's blood. PAPPa is produced by the placenta, while Free HCG is produced by the developing baby. The levels of these markers can help identify chromosomal abnormalities in the baby.

• This test is done to:
• Screen for chromosomal abnormalities in the 1st trimester
• Assess risk for Down syndrome, Edwards syndrome, and Patau syndrome
• Screen for Trisomy 21 (Down syndrome), Trisomy 18 (Edwards syndrome), and Trisomy 13 (Patau syndrome)
• Guide doctors in providing suitable care and support

This test is recommended for pregnant women between 8 to 13.6 weeks of gestation. It is suitable for all pregnant women who want to assess their baby's risk for chromosomal abnormalities. Additionally, it may be suggested for women with a history of previous chromosomal abnormalities or those at higher risk based on certain genetic factors.

The test results are interpreted based on the levels of PAPPa and Free HCG in the blood. Abnormal results may indicate an increased risk of chromosomal abnormalities in the baby, but it does not provide a definitive diagnosis. Further diagnostic tests like genetic counselling or invasive prenatal testing may be recommended to confirm any abnormalities.

During this test, a small sample of your blood will be collected from your arm. It is a quick and simple procedure that usually takes a few minutes to complete. The sample will then be sent to the laboratory for analysis.

Before the test, make sure to provide a completely filled maternal TRF with a barcode and an ultrasound report. You may need to schedule an appointment at the designated time for blood collection. It is essential to follow any specific instructions given by your doctor or healthcare provider before taking the test

In conjunction with the Maternal Screen-1st Trimester Dual Marker Test (Serum), doctors may recommend additional tests such as detailed fetal ultrasound, non-invasive prenatal testing (NIPT), or invasive prenatal diagnostic tests like chorionic villus sampling (CVS) or amniocentesis to further evaluate any identified abnormalities.

 1st Trimester Screen, First-Trimester Combined Screening or Maternal Serum Screening

Down syndrome is a genetic disorder caused by the presence of an extra copy of chromosome 21. Edwards syndrome (Trisomy 18) and Patau syndrome (Trisomy 13) are also chromosomal disorders caused by the presence of extra chromosome 18 and chromosome 13, respectively. These conditions can lead to various physical and intellectual disabilities.